SEC Tracker
Get the app

OnKure Therapeutics OKUR

Report of Independent Registered Public Accounting Firm

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.14
Material contract
Exhibit 10.15
Material contract
Exhibit 10.16
Material contract
Exhibit 10.17
Material contract
Exhibit 10.18
Material contract
Exhibit 10.19
Material contract
Exhibit 10.20
Material contract
Exhibit 10.21
Material contract
Exhibit 10.22
Material contract
Exhibit 10.23
Material contract
Exhibit 99.1
Press release
  • Completes an acquisition or sale of assets (2.01)
  • Sells unregistered shares (3.02)
  • Changes shareholder rights (3.03)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Changes its ethics code (5.05)
  • Changes its shell company status (5.06)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when OnKure Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Champions Oncology CSBR public float $29M, Oct 31, 2025
  2. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  3. Outlook Therapeutics OTLK public float $27M, Mar 31, 2025, over 18 months old
  4. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  5. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.